Neuroendocrine Differentiation of Prostate Cancer Is Not Systematically Associated with Increased 18F-FDG Uptake

Neuroendocrine Differentiation of Prostate Cancer Is Not Systematically Associated with Increased 18F-FDG Uptake

Neuroendocrine differentiation (NED) of prostate cancer represents an acknowledged predictor of resistant and more aggressive disease. NED can be functionally exploited in vivo using PET/CT imaging with somatostatin analogs radiolabeled with 68Ga. Many previous reports have shown that 18F-FDG PET/CT...

Full description

Bibliographic Details
Main Authors:	Matteo Bauckneht, Silvia Morbelli, Alberto Miceli, Sara Elena Rebuzzi, Giuseppe Fornarini
Format:	Article
Language:	English
Published:	MDPI AG 2021-03-01
Series:	Diagnostics
Subjects:	metastatic castration-resistant prostate cancer neuroendocrine differentiation positron emission tomography 18F-Fluorodeoxyglucose 68Ga-Dotatoc
Online Access:	https://www.mdpi.com/2075-4418/11/3/468

Similar Items

Beyond the Prognostic Value of 2-[<sup>18</sup>F]FDG PET/CT in Prostate Cancer: A Case Series and Literature Review Focusing on the Diagnostic Value and Impact on Patient Management
by: Roberto Borea, et al.
Published: (2022-02-01)

Contemporary nuclear medicine diagnostics of neuroendocrine tumors
by: Todorović-Tirnanić Mila, et al.
Published: (2015-01-01)

Cutting-Edge Imaging of Cardiac Metastases from Neuroendocrine Tumors: Lesson from a Case Series
by: Soraya El Ghannudi, et al.
Published: (2022-05-01)

Comparison of 18F-FDG and 68-PSMA-11 in PET for prostate cancer diagnosis
by: Natalia Fulle, et al.
Published: (2022-12-01)

Quantification of standardised uptake value for ¹⁸F-FDG positron emission tomography in Malaysia
by: Hanafi, Muhammad Hafiz
Published: (2017)

Impact of segmentation and discretization on radiomic features in 68Ga-DOTA-TOC PET/CT images of neuroendocrine tumor
by: Virginia Liberini, et al.
Published: (2021-02-01)

Comparison of diagnostic efficacy of 18F-FDG PET/CT and 68Ga-DOTANOC PET/CT in ectopic adrenocorticotropic hormone syndrome
by: Bing Zhang, et al.
Published: (2022-09-01)

Relationship between sex hormones levels and 18F-FDG uptake by the ovaries in premenopausal woman
by: Kim Tae Hee, et al.
Published: (2019-09-01)

The potential application of MR-derived ADCmin values from 68Ga-DOTATATE and 18F-FDG dual tracer PET/MR as replacements for FDG PET in assessment of grade and stage of pancreatic neuroendocrine tumors
by: Jing Gao, et al.
Published: (2023-02-01)

The Relationship Between KRAS Mutation and 18F-FDG Uptake Parameters in Colorectal Cancer
by: Aynur Özen, et al.
Published: (2022-06-01)

Reflecting on the utility of standardized uptake values on 18F-FDG PET in nasopharyngeal carcinoma
by: Xiufang Qiu, et al.
Published: (2022-05-01)

Intrapancreatic accessory spleen false positive to 68Ga-Dotatoc: case report and literature review
by: Francesco Lancellotti, et al.
Published: (2019-07-01)

Dual Tracer 68Ga-DOTATOC and 18F-FDG PET Improve Preoperative Evaluation of Aggressiveness in Resectable Pancreatic Neuroendocrine Neoplasms
by: Paola Mapelli, et al.
Published: (2021-01-01)

Pulmonary large cell neuroendocrine carcinoma (LCNEC) with confirmed liver metastases negative on 18F-FDG and 68Ga-DOTATATE PET
by: Gaia Ninatti, et al.
Published: (2020-12-01)

A prospective study on dual time 18F-FDG-PET/CT in high-risk prostate cancer patients
by: Mike Allan Mortensen, et al.
Published: (2018-12-01)

Prognostic Value of CT-Attenuation and <sup>18</sup>F-Fluorodeoxyglucose Uptake of Periprostatic Adipose Tissue in Patients with Prostate Cancer
by: Jeong Won Lee, et al.
Published: (2020-10-01)

Development of an Automated Synthesizer for the Routine Production of Ga-68 Radiopharmaceuticals
by: Jun Young PARK, et al.
Published: (2023-12-01)

The 18F-FDG PET scan in oncology
by: T Thientunyakit
Published: (2007-12-01)

Diagnostic work-up of gastroenteropancreatic neuroendocrine tumors
by: Kjell Öberg
Published: (2012-01-01)

Changes in biodistribution on 68Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression
by: Martin H. Cherk, et al.
Published: (2018-01-01)

Target Heterogeneity in Oncology: The Best Predictor for Differential Response to Radioligand Therapy in Neuroendocrine Tumors and Prostate Cancer
by: Ameya D Puranik, et al.
Published: (2021-07-01)

Frequency and Clinical Significance of Incidental Prostatic FDG uptake in FDG PET imaging
by: Elif Özdemir, et al.
Published: (2020-06-01)

Is Prone Position [<sup>18</sup>F]FDG PET/CT Useful in Reducing Respiratory Motion Artifacts in Evaluating Hepatic Lesions?
by: Chung Won Lee, et al.
Published: (2023-07-01)

The Evolving Role of 18F-FDG PET/CT in Diagnosis and Prognosis Prediction in Progressive Prostate Cancer
by: Kai Shen, et al.
Published: (2021-07-01)

Mechanisms of castration resistant prostate cancer formation and progression through neuroendocrine differentiation
by: Xueping Ma, et al.
Published: (2021-09-01)

Evaluation of Age and Sex-Related Metabolic Changes in Healthy Subjects: An Italian Brain 18F-FDG PET Study
by: Michela Allocca, et al.
Published: (2021-10-01)

Personalized 18FDG Dose Synthesis Using BG-75 Generator: 1st Year Experience at JCI Accredited Tertiary Care Hospital in Pakistan
by: Zaman M. U., et al.
Published: (2019-08-01)

18FDG PET in lymphoma
by: Goldsmith Stanley J.
Published: (2012-01-01)

Receptor depletion and recovery in small-intestinal neuroendocrine tumors and normal tissues after administration of a single intravenous dose of octreotide measured by 68Ga-DOTATOC PET/CT
by: Ulrika Jahn, et al.
Published: (2021-11-01)

Characteristics of 18F⁃FDG PET in Creutzfeldt⁃Jakob disease
by: LIN Xue, et al.
Published: (2021-05-01)

Diagnostic Impact of Dual-Time PET/CT with <sup>68</sup>Gallium-PSMA in Prostate Cancer and <sup>68</sup>Gallium-DOTATOC in Neuroendocrine Tumors
by: Damiano Librizzi, et al.
Published: (2023-03-01)

18F-FDG PET/CT in therapy response assessment: oligometastatic colorectal cancer
by: Ibrahim Mansour Nasr, et al.
Published: (2023-02-01)

Comparison of 68Ga-DOTANOC and 18F-FDG PET-CT Scans in the Evaluation of Primary Tumors and Lymph Node Metastasis in Patients With Rectal Neuroendocrine Tumors
by: Zhihao Zhou, et al.
Published: (2021-09-01)

Application of 68Ga-PSMA-11 and 18F-PSMA-1007 in prostate cancer
by: Hu Siqi, Zhang Yong
Published: (2022-01-01)

Role of MicroRNAs in Neuroendocrine Prostate Cancer
by: Amritha Sreekumar, et al.
Published: (2022-03-01)

Realizing 32-time Scan Duration Reduction of 18F-FDG PET Using Deep Learning Model with Image Augmentation
by: Ali Ghafari, et al.
Published: (2022-08-01)

The Current Therapeutic Landscape for Metastatic Prostate Cancer
by: Anastasia Bernal, et al.
Published: (2024-03-01)

Gastrointestinal neuroendocrine tumor with discordant metastatic disease on 111In-pentetreotide SPECT/CT, 18F-DOPA PET/CT and 68Ga-HA-DOTATATE PET/CT
by: Katrin Resch, et al.
Published: (2022-07-01)

The Additional Value of Somatostatin Receptor Positron Emission Computed Tomography ([<sup>68</sup>Ga]Ga-DOTATOC PET/CT) Compared with Magnetic Resonance Imaging of the Head and Neck Region in Paraganglioma Patients: A Pilot Study
by: Carolijn J. M. de Bresser, et al.
Published: (2024-02-01)

Relationship of FDG Uptake of the Reticuloendothelial System with Tumor Immune Microenvironment and Prognosis in Patients with Gastric Cancer
by: Hyein Ahn, et al.
Published: (2023-03-01)